Association of Glycemic Control With Reduced Risk for Large-Vessel Disease After More Than 50 Years of Type 1 Diabetes

Context Previously we demonstrated, in individuals who have had type 1 diabetes (T1D) for 50 or more years (Medalists), that glycemic control was unrelated to diabetic complications, with the exception of cardiovascular disease (CVD), contrary to what has been documented in registry-based studies. Objective The purpose of this study is to validate these initial findings and identify contributors to mortality on an individual basis in a large cohort. Design Cross-sectional and longitudinal study. Setting Joslin Diabetes Center (JDC), Boston, Massachusetts. Patients 50-year Medalists presenting to JDC for study participation. Interventions None. Main Outcomes Measures Microvascular and macrovascular complications of diabetes and mortality. Results Glycemic control was not significantly associated with small-vessel complications in Medalists but was associated with CVD in the overall cohort, yet with varying effect by tertile of cohort duration. CVD was the largest contributor to mortality, whereas hemoglobin A1c was not an independent predictor of mortality either overall or substantially by diagnosis interval. Additionally, exercise mitigated mortality risk imparted by CVD. Conclusions Few large populations with long duration of (T1D) have been available to examine the effects of long-term exposure to hyperglycemia. These data indicate that an association of glycemic control, complications, and mortality may change in an older population with T1D. These results suggest that careful control is still warranted in older populations with T1D.

[1]  S. Ghose Glycemic Targets , 2018, TAJ: Journal of Teachers Association.

[2]  K. Close,et al.  American Diabetes Association 77th Scientific Sessions , 2017, Journal of diabetes.

[3]  T. Skrivarhaug,et al.  Long-term Mortality and End-Stage Renal Disease in a Type 1 Diabetes Population Diagnosed at Age 15–29 Years in Norway , 2016, Diabetes Care.

[4]  J. Shaw,et al.  Age-Specific Trends From 2000–2011 in All-Cause and Cause-Specific Mortality in Type 1 and Type 2 Diabetes: A Cohort Study of More Than One Million People , 2016, Diabetes Care.

[5]  P. Clarke,et al.  Recent trends in life expectancy for people with type 1 diabetes in Sweden , 2016, Diabetologia.

[6]  G. King,et al.  PKCδ inhibition normalizes the wound-healing capacity of diabetic human fibroblasts. , 2016, The Journal of clinical investigation.

[7]  S. Wild,et al.  Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals , 2016, Diabetologia.

[8]  T. Byers Excess Mortality among Persons with Type 2 Diabetes. , 2016, The New England journal of medicine.

[9]  D. Giugliano,et al.  Reducing glucose variability with continuous subcutaneous insulin infusion increases endothelial progenitor cells in type 1 diabetes: an observational study , 2016, Endocrine.

[10]  J. Shaw,et al.  Life expectancy of type 1 diabetic patients during 1997–2010: a national Australian registry-based cohort study , 2016, Diabetologia.

[11]  A. Rosengren,et al.  Excess Mortality among Persons with Type 2 Diabetes. , 2015, The New England journal of medicine.

[12]  Jennifer K. Sun,et al.  Cardiovascular Disease Protection in Long-Duration Type 1 Diabetes and Sex Differences , 2015, Diabetes Care.

[13]  B. Zinman,et al.  Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. , 2015, JAMA.

[14]  Jennifer K. Sun,et al.  Characterization of Circulating and Endothelial Progenitor Cells in Patients With Extreme-Duration Type 1 Diabetes , 2014, Diabetes Care.

[15]  J. Coresh,et al.  Lifetime incidence of CKD stages 3-5 in the United States. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  Thomas J. Songer,et al.  Improvements in the Life Expectancy of Type 1 Diabetes , 2012, Diabetes.

[17]  S. Wild,et al.  Risk of Cardiovascular Disease and Total Mortality in Adults with Type 1 Diabetes: Scottish Registry Linkage Study , 2012, PLoS medicine.

[18]  Jennifer K. Sun,et al.  Protection From Retinopathy and Other Complications in Patients With Type 1 Diabetes of Extreme Duration , 2011, Diabetes Care.

[19]  S. Kelsey,et al.  Cause-Specific Mortality Trends in a Large Population-Based Cohort With Long-Standing Childhood-Onset Type 1 Diabetes , 2010, Diabetes.

[20]  R. G. Miller,et al.  In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study , 2010, Diabetologia.

[21]  T. Travison,et al.  Does erectile dysfunction contribute to cardiovascular disease risk prediction beyond the Framingham risk score? , 2010, Journal of the American College of Cardiology.

[22]  Ronald Klein,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. , 2008, Ophthalmology.

[23]  Jennifer K. Sun,et al.  Clinical Factors Associated With Resistance to Microvascular Complications in Diabetic Patients of Extreme Disease Duration , 2007, Diabetes Care.

[24]  T. Skrivarhaug,et al.  Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway , 2006, Diabetologia.

[25]  I. Thompson,et al.  Erectile dysfunction and subsequent cardiovascular disease. , 2005, JAMA.

[26]  Douglas W Mahoney,et al.  Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. , 2004, Journal of clinical epidemiology.

[27]  G. Gill,et al.  Characteristics of Type 1 diabetes of over 50 years duration (the Golden Years Cohort) , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[28]  E. Rimm,et al.  Sexual Function in Men Older Than 50 Years of Age: Results from the Health Professionals Follow-up Study , 2003, Annals of Internal Medicine.

[29]  A. J. Swerdlow,et al.  Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes , 2003, Diabetologia.

[30]  N. Calonge,et al.  Validation of self-reported chronic conditions and health services in a managed care population. , 2000, American journal of preventive medicine.

[31]  M M Bergmann,et al.  Validity of self-reported diagnoses leading to hospitalization: a comparison of self-reports with hospital records in a prospective study of American adults. , 1998, American journal of epidemiology.

[32]  The Relationship of Glycemic Exposure (HbA1c) to the Risk of Development and Progression of Retinopathy in the Diabetes Control and Complications Trial , 1995, Diabetes.

[33]  Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. , 1995, The American journal of cardiology.

[34]  M B Brown,et al.  A Practical Two-Step Quantitative Clinical and Electrophysiological Assessment for the Diagnosis and Staging of Diabetic Neuropathy , 1994, Diabetes Care.

[35]  H A Feldman,et al.  Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. , 1994, The Journal of urology.

[36]  B E Ainsworth,et al.  Accuracy of the College Alumnus Physical Activity Questionnaire. , 1993, Journal of clinical epidemiology.

[37]  L. Kuller,et al.  Lipoprotein(a) Concentration Shows Little Relationship to IDDM Complications in the Pittsburgh Epidemiology of Diabetes Complications Study Cohort , 1993, Diabetes Care.

[38]  R. Klein,et al.  Cause-specific mortality in a population-based study of diabetes. , 1991, American journal of public health.

[39]  Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. , 1991, Ophthalmology.